Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13603061 | 0.88 | BRAF (0.44) | BRAFPDGFRAKDR | |
| SCHEMBL2603673 | 0.87 | BRAF (0.47) | BRAFPDGFRA | |
| SCHEMBL13603256 | 0.84 | PSMB8 (0.43) | BRAF | |
| SCHEMBL13610876 | 0.80 | AURKA (0.40) | BRAFPDGFRAKDR | |
| SCHEMBL13610853 | 0.79 | BRAF (0.70) | BRAF | |
| SCHEMBL4458348 | 0.78 | AURKA (0.54) | BRAF | |
| SCHEMBL13603043 | 0.77 | FGFR2 (0.42) | BRAFKDR | |
| SCHEMBL12615718 | 0.76 | BRAF (0.45) | BRAFPDGFRA | |
| SCHEMBL2603635 | 0.76 | BRAF (0.46) | BRAF | |
| SCHEMBL2603675 | 0.76 | MEN1 (0.46) | BRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625922-B2 | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | NR2E1, NR0B1, BRAF | BRAF 3/4885PDGFRA 1561/4885KDR 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.